UCB, ChemDiv end first phase of collaborative discovery chemistry program

As part of a complete discovery chemistry solution ChemDiv prepared complex and highly targeted medicinal chemical scaffolds, building blocks and templates.

UCB spokesperson Benoit Kenda said, "UCB had been looking for a partner that has a very strong standing in scaffolds ideation, library preparation and could contribute to UCB’s already large and diverse compounds library, in particular in developing special libraries, according to UCB’s specifications, and need to inhibit novel Biotargets."

The partners’ joint steering committee review of progress milestones confirmed the success of the ongoing collaboration, which carries an initial term of two years, and can further be extended.

ChemDiv Research Institute CEO Dmitry Kravchenko said, "Our success in developing this comprehensive chemistry solution for UCB was enabled by ChemDiv’s proprietary Chemistry On Demand design and development system, which encompasses over 2B of druggable, target-relevant and validated structure/synthetic space."